Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.

Liberti L, Stolk P, McAuslane JN, Schellens J, Breckenridge AM, Leufkens H.

Oncologist. 2015 Jun;20(6):683-91. doi: 10.1634/theoncologist.2014-0297. Epub 2015 May 6.

2.

Mini-Sentinel and regulatory science--big data rendered fit and functional.

Psaty BM, Breckenridge AM.

N Engl J Med. 2014 Jun 5;370(23):2165-7. doi: 10.1056/NEJMp1401664. No abstract available.

PMID:
24897081
3.

The UK's NHS and pharma: need for more clinical pharmacologists.

Aronson JK, Barnett DB, Breckenridge AM, Ferner RE, Jackson P, Maxwell SR, McInnes GT, Rawlins MD, Ritter JM, Routledge P, Walley TJ, Webb DJ, Williams D, Woods KL.

Lancet. 2009 Apr 11;373(9671):1251-2. doi: 10.1016/S0140-6736(09)60726-1. No abstract available.

PMID:
19362673
4.

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM.

BMJ. 2004 Jul 3;329(7456):15-9.

5.

Reporting of adverse drug reactions by nurses.

Morrison-Griffiths S, Walley TJ, Park BK, Breckenridge AM, Pirmohamed M.

Lancet. 2003 Apr 19;361(9366):1347-8.

PMID:
12711472

Supplemental Content

Loading ...
Support Center